Related Experiment Video
Updated: Jun 14, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Development of a patient/proxy-reported instrument for pediatric antibiotic-associated diarrhea
Samaneh Khanpour Ardestani1, Joan L Robinson1, Hsing Jou1
1Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Insights
This study developed a new tool to measure pediatric antibiotic-associated diarrhea (PAAD). The developed instrument shows promise for assessing PAAD incidence and severity in children.
Area of Science:
- Pediatric Gastroenterology
- Clinical Trial Methodology
- Patient-Reported Outcomes
Background:
- Antibiotic-associated diarrhea (AAD) is a common adverse effect in children.
- Existing measures do not adequately capture the incidence and severity of pediatric AAD.
- A validated patient/proxy-reported measure is needed for both inpatient and outpatient settings.
Purpose of the Study:
- To develop and validate a patient/proxy-reported instrument for pediatric antibiotic-associated diarrhea (PAAD).
- To assess the incidence and severity of PAAD in pediatric populations.
- To establish content and construct validity of the new PAAD measure.
Main Methods:
- Engaged a patient advisory group in the development process.
- Developed instrument items from existing validated instruments, a core outcome measurement set, and stakeholder input.
- Conducted a prospective observational study of children (birth to 17 years) prescribed antibiotics, assessing them daily for two weeks post-therapy.
Main Results:
- Analyzed data from 48 eligible participants after 38% loss to follow-up.
- Reported a wide range of PAAD incidence risks (27%-83%) based on different definitions.
- Observed higher PAAD incidence in younger children (≤ 3 years) and found significant correlation between the PAAD severity score and parent-reported severity.
Conclusions:
- The developed PAAD instrument is the first of its kind for measuring incidence and severity.
- The instrument demonstrates content and construct validity.
- Larger studies are recommended to further analyze the reliability of the severity scale.
Objective:
To develop and validate a patient/proxy-reported measure of the incidence and severity of pediatric antibiotic-associated diarrhea (PAAD) in inpatient and outpatient settings.
Methods:
A patient advisory group, consisting of five parents and two children, was engaged as a research partner. Instrument items were developed from three sources: relevant items from two previously validated instruments; relevant constructs from a newly developed core outcome measurement set; and outcomes identified by parents and clinicians as being the most important. In a prospective observational study, children (birth to 17 years old) newly prescribed antibiotics or on antibiotics for ≤ 7 days, were included and assessed at the time of presentation and daily thereafter until two weeks after antibiotic therapy was completed. Internal consistency and convergent validity of the instrument were examined.
Results:
Of 78 patients who agreed to participate and met the eligibility criteria, 30(38%) were lost to follow-up; Data from the remaining 48 were analyzed. By applying four different definitions of diarrhea, we found a broad range of incidence risks of PAAD (27%-83%). PAAD was more likely to develop in younger age groups (≤ 3 years old). Cronbach's α for the severity scale was less than 0.7. A high correlation was found between the PAAD severity score and numerical rating score of diarrhea severity reported by parents (r > 0.5).
Conclusion:
The PAAD instrument is the first designed to measure the incidence and severity of PAAD. The instrument has content and construct validity. For reliability analyses of the severity scale, larger studies are required.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024